- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT04796545
Investigación clínica del sistema Tsert SI, modelo NG SI IMT 3X en pacientes con degeneración macular relacionada con la edad en etapa terminal
Una investigación clínica prospectiva, multicéntrica posterior a la comercialización del sistema Tsert SITM, modelo NG SI IMT 3X en pacientes con deterioro de la visión central asociado con degeneración macular relacionada con la edad en etapa terminal
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision impairment associated with end-stage Age-related Macular Degeneration (AMD).
Eligible patients will be implanted with the SING IMT device and will be followed-up for a period of 12-months with post-operative ophthalmic exams and low-vision rehabilitation sessions.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This is an interventional, prospective, multicenter, open label, single group assignment Post-Market Clinical Follow-up (PMCF) study in men and women >=55 years with central vision impairment associated with end-stage AMD.
Following completion of informed consent, patients will be evaluated for eligibility to enroll into the study. Baseline visual acuity of the study subjects will be assessed with a 2.8X external telescope simulator (ETS) using Early Treatment Diabetic Retinopathy Study (ETDRS) charts to determine if they are likely to benefit from receiving the IMT. To be included in the study and to proceed with the surgery, subjects must achieve, using the ETS, at least a one line (5 or more letters) improvement in distance on the ETDRS chart in the eye scheduled for surgery. Subjects not meeting these criteria will be excluded from the study.
If eligible, they will be scheduled for out-patient surgery to implant the IMT during routine cataract surgery.
Postoperatively, the surgeon will complete a usability and satisfaction questionnaire after each implantation procedure.
The patients will undergo ophthalmic evaluations in both eyes at regular intervals for up to 12 months. The subjects will also be required to undergo 6 to 10 additional visits for vision training with a low vision specialist.
Surgical complications, as well as all Adverse Event (AEs) and use of medications will be monitored from baseline to the end of the study.
Tipo de estudio
Inscripción (Actual)
Fase
- No aplica
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Karlsruhe, Alemania
- Augenklinik Städtisches Klinikum Karlsruhe
-
Münster, Alemania
- Universitätsklinikum Münster Klinik für Augenheilkunde
-
-
-
-
-
Brussels, Bélgica
- UZ Brussel
-
-
-
-
-
Alicante, España
- VISSUM
-
Barcelona, España
- Institut OMIQ
-
Madrid, España
- Hospital Universitario La Luz - Quirónsalud
-
-
-
-
-
Marseille, Francia
- Centre d'Ophtalmologie Paradis-Monticelli
-
Saint-Jean-de-Luz, Francia
- Hélios Ophtalmologie, Saint-Jean-de-Luz
-
Strasbourg, Francia
- CHRU de Strasbourg
-
-
-
-
-
Dublin, Irlanda
- Mater Misericordiae University Hospital
-
-
-
-
-
Naples, Italia
- Università degli Studi di Napoli Federico II
-
Roma, Italia
- Fondazione Policlinico Universitario Agostino Gemelli
-
-
-
-
-
Belfast, Reino Unido
- Royal Victoria Hospital Belfast Health & Social Care Trust
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Be 55 years of age or older.
- Have retinal findings of geographic atrophy or disciform scar with foveal involvement as determined by fluorescein angiography or OCT.
- Have evidence of cataract.
- Have best-corrected distance visual acuity (BCDVA) no better than 20/80 (0.6 LogMAR) and no worse than 20/800 (1.6 LogMAR) in both eyes.
- Have adequate peripheral vision in the eye not scheduled for surgery, assessed by observation of ambulation.
- Achieve at least a five-letter improvement on the ETDRS chart in the eye scheduled for surgery when using Samsara's 2.8X external telescope simulator (ETS, supplied separately).
- Have an ACD of at least 2.5 mm in the eye scheduled for surgery.
- Be willing to participate in a post-operative training program for the use of the NG SI IMT 3X implant.
- Review and sign the Independent Ethics Committee (IEC)-approved Informed Consent Form (ICF) prior to any study-related procedures being performed.
- Have adequate understanding of the local language to understand verbal and written subject information and be willing to comply with the study requirements.
Exclusion Criteria:
-
Evidence of active choroidal neovascularization (CNV) on fluorescein angiography or OCT or were treated for CNV within the past six months.
-
Any ophthalmic pathology that compromises the patient's peripheral vision in the fellow eye.
-
A history of steroid-responsive rise in IOP, uncontrolled glaucoma, or preoperative IOP>22 mm Hg.
-
Corneal guttata.
-
Known sensitivity to post-operative medications.
-
Significant communication impairment or severe neurological disorders.
-
Have undergone previous intraocular or corneal surgery of any kind in the operative eye, including any type of surgery for either refractive or therapeutic purposes.
-
An ocular condition that predisposes the patient to eye rubbing.
-
Prior or expected ophthalmic-related surgery within 30 days preceding the NG SI IMT 3X implant surgery.
-
Patients for whom the planned operative eye has:
- Myopia > 6.0 D
- Hyperopia > 4.0 D
- Axial length < 21 mm
- Endothelial cell density < 1600 cells per square mm
- Narrow angle, i.e., < Schaffer grade 2.
-
Inflammatory ocular disease.
-
Cornea stromal or endothelial dystrophies, including guttata.
-
Zonular weakness/instability of crystalline lens, or pseudoexfoliation.
-
Diabetic retinopathy.
-
Untreated retinal tears.
-
Retinal vascular disease.
-
Optic nerve disease.
-
A history of retinal detachment.
-
Retinitis pigmentosa.
-
Intraocular tumor.
-
Have received any investigational product within 30 days prior to study enrollment or be planning to participate in another investigation during the course of this study.
-
Be an employee (or a relative of an employee) of the contract research organization (CRO) responsible for conducting the study, Sponsor, or Sponsor representative.
-
Have a condition or be in a situation that, in the Investigator's opinion, may put the Subject at significant risk, may confound the study results, or may interfere significantly with the Subject's participation in the study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Otro
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: SING IMT System model NG SI IMT 3X
All participants will be implanted with the SING IMT System model NG SI IMT 3X. |
The SING IMT 3X implant is a visual prosthetic implantable device, which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with bilateral, end-stage age-related macular degeneration. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Safety of the SING IMT System, model NG SI IMT 3X, including its delivery system
Periodo de tiempo: 12 months
|
The percent decrease in endothelial cell density (ECD). |
12 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Incision size needed for device implantation
Periodo de tiempo: 12 moths
|
Incision size will not exceed 8.0 mm (non-inferiority assumption) in 75% of surgeries |
12 moths
|
|
Surgical complications
Periodo de tiempo: 12 moths
|
AEs and serious adverse events |
12 moths
|
|
Improvement in near and distance best corrected visual acuity (BCVA) in implanted eyes.
Periodo de tiempo: 12 months
|
Near and distance BCVA will show an improvement of ≥2 lines in the ETDRS chart in at least 50% (non-inferior to 50%) of the implanted eyes at 12 months post implantation. |
12 months
|
|
Usability of SING IMT System, including delivery system
Periodo de tiempo: 12 months
|
Surgeon will complete a usability and satisfaction questionnaire |
12 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Device stability and fixation
Periodo de tiempo: 12 months
|
Assessed by slit lamp biomicroscopy examination: device tilt and device decentration |
12 months
|
|
Post-operative anterior chamber depth (ACD)
Periodo de tiempo: 12 months
|
Anterior Chamber Depth (ACD) evaluated by ultrasound biomicroscopy (UBM), ocular coherence tomography (OCT) or another applicable test method |
12 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- SING IMT PMCF
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .